Head to head

Motus AZ+ vs Motus PRO (2026)

Compare purchase costs, running costs and the evidence behind each device.

Read the comparison overview

Purchase cost: The catalog lists $120k–$160k for Motus AZ+. No new-price range is on file for Motus PRO. Check the source notes and request current quotes.
Practice fit: Motus AZ+: dual-wavelength (in-motion). Motus PRO: alexandrite laser (in-motion). Check each model’s US regulatory status and labeled indications for your intended use.

Device A

Dual-wavelength (in-motion)

View full device profile →

Device B

Alexandrite laser (in-motion)

View full device profile →

Price comparison

Price comparison: DEKA Motus AZ+ vs DEKA Motus PRO
Attribute	DEKA Motus AZ+	DEKA Motus PRO
New price range	$120k–$160kSource not documented	Not published
Used asking range	$80k–$110kSource not documented	Not published
Payback calculator	View ROI calculator	View cost details
Next step

New price range

DEKA Motus AZ+: $120k–$160kSource not documented
DEKA Motus PRO: Not published

Used asking range

DEKA Motus AZ+: $80k–$110kSource not documented
DEKA Motus PRO: Not published

Payback calculator

DEKA Motus AZ+: View ROI calculator
DEKA Motus PRO: View cost details

Next step

DEKA Motus AZ+

DEKA Motus PRO

Consumable economics

Consumable economics: DEKA Motus AZ+ vs DEKA Motus PRO
Attribute	DEKA Motus AZ+	DEKA Motus PRO
Consumable cost / lock-in	No per-treatment consumables — gel and eventual sapphire-tip wear; a few thousand a year in maintenance reserve.	Supply pricing is not documented with a dated source yet. Request an itemized supply quote.
Service cost	Not published	Not published

Consumable cost / lock-in

DEKA Motus AZ+: No per-treatment consumables — gel and eventual sapphire-tip wear; a few thousand a year in maintenance reserve.
DEKA Motus PRO: Supply pricing is not documented with a dated source yet. Request an itemized supply quote.

Service cost

DEKA Motus AZ+: Not published
DEKA Motus PRO: Not published

FDA clearance

FDA clearance: DEKA Motus AZ+ vs DEKA Motus PRO
Attribute	DEKA Motus AZ+	DEKA Motus PRO
FDA status & indication	FDA ClearedK211821, K162886, K181486 Read FDA indication wording “Alexandrite 755nm laser source: Temporary hair reduction. Stable long-term or permanent hair reduction through selective targeting of melanin in hair follicles. Permanent hair reduction is defined as the long-term, stable reduction in the number of hairs regrowing when measured at 6,9, and 12 months after the completion of a treatment regime, on all skin types (Fitzpatrick I – VI) including tanned skin. Treatment of benign pigmented lesions. Treatment of wrinkles. Photocoagulation of benign dermatological vascular lesions (such as port-wine stains, hemangiomas, telangiectasias). Nd:YAG 1064nm laser source: Removal of unwanted hair, for stable long term or permanent hair reduction and for treatment of PFB. The lasers are indicated on all Skin Types Fitzpatrick I-VI including tanned skin. Photocoagulation and hemostasis of benign pigmented and benign vascular lesions, such as but not limited to port wine stains, hemangioma, warts, teleangiectasia, rosacea, venus lake, leg veins and spider veins. Coagulation and hemostasis of soft tissue. Benign pigmented lesions such as, but not limited to, lentigos, (age spots), solar lentigos (sun spots), cafe au lait macules, seborrheic keratosis, nevi, cloasma, verrucae, skin tags, keratosis and plaques. The laser is indicated for benign pigmented lesions to reduce lesion size, for patients with lesions that would potentially benefit from aggressive treatment, and for patients with lesions that have not responded to other laser treatments. The laser is also indicated for the reduction of red pigmentation in hypertrophic and keloid scars where vascularity is an integral part of the scar. Treatment of wrinkles.”	FDA ClearedK241459 Read FDA indication wording “The MOTUS PRO family is a medical device laser family intended for: Alexandrite 755nm laser source: • Temporary hair reduction. • Stable long term or permanent hair reduction through selective targeting of melanin in hair follicles. • Permanent hair reduction is defined as the long term, stable reduction in the number of hairs regrowing when measured at 6,9 and 12 months after the completion of a treatment regime on all skin types (Fitzpatrick I-VI) including tanned skin. • Treatment of benign pigmented lesions. • Photocoagulation of benign dermatological vascular lesions (such as port-wine stains, hemangiomas, telangiectasias). Nd:YAG 1064nm laser source: • Removal of unwanted hair, for stable long term or permanent hair reduction and for treatment of PFB. The lasers are indicated on all Skin Types Fitzpatrick I-VI including tanned skin. • Photocoagulation and hemostasis of benign pigmented and benign vascular lesions, such as but not limited to port wine stains, hemangioma, warts, teleangiectasia, rosacea, venous lake, leg veins and spider veins. • Coagulation and hemostasis of soft tissue. • Benign pigmented lesions such as, but not limited to, lentigos, (age spots), solar lentigos (sun spots), café au lait macules, seborrheic keratosis, nevi, cloasma, verrucae, skin tags, keratosis and plaques. • The laser is indicated for benign pigmented lesions to reduce lesion size, for patients with lesions that would potentially benefit from aggressive treatment, and for patients with lesions that have not responded to other laser treatments. • The laser is also indicated for the reduction of red pigmentation in hypertrophic and keloid scars where vascularity is an integral part of the scar. • Treatment of wrinkles.”

FDA status & indication

DEKA Motus AZ+: FDA ClearedK211821, K162886, K181486
Read FDA indication wording
“Alexandrite 755nm laser source: Temporary hair reduction. Stable long-term or permanent hair reduction through selective targeting of melanin in hair follicles. Permanent hair reduction is defined as the long-term, stable reduction in the number of hairs regrowing when measured at 6,9, and 12 months after the completion of a treatment regime, on all skin types (Fitzpatrick I – VI) including tanned skin. Treatment of benign pigmented lesions. Treatment of wrinkles. Photocoagulation of benign dermatological vascular lesions (such as port-wine stains, hemangiomas, telangiectasias). Nd:YAG 1064nm laser source: Removal of unwanted hair, for stable long term or permanent hair reduction and for treatment of PFB. The lasers are indicated on all Skin Types Fitzpatrick I-VI including tanned skin. Photocoagulation and hemostasis of benign pigmented and benign vascular lesions, such as but not limited to port wine stains, hemangioma, warts, teleangiectasia, rosacea, venus lake, leg veins and spider veins. Coagulation and hemostasis of soft tissue. Benign pigmented lesions such as, but not limited to, lentigos, (age spots), solar lentigos (sun spots), cafe au lait macules, seborrheic keratosis, nevi, cloasma, verrucae, skin tags, keratosis and plaques. The laser is indicated for benign pigmented lesions to reduce lesion size, for patients with lesions that would potentially benefit from aggressive treatment, and for patients with lesions that have not responded to other laser treatments. The laser is also indicated for the reduction of red pigmentation in hypertrophic and keloid scars where vascularity is an integral part of the scar. Treatment of wrinkles.”
DEKA Motus PRO: FDA ClearedK241459
Read FDA indication wording
“The MOTUS PRO family is a medical device laser family intended for: Alexandrite 755nm laser source: • Temporary hair reduction. • Stable long term or permanent hair reduction through selective targeting of melanin in hair follicles. • Permanent hair reduction is defined as the long term, stable reduction in the number of hairs regrowing when measured at 6,9 and 12 months after the completion of a treatment regime on all skin types (Fitzpatrick I-VI) including tanned skin. • Treatment of benign pigmented lesions. • Photocoagulation of benign dermatological vascular lesions (such as port-wine stains, hemangiomas, telangiectasias). Nd:YAG 1064nm laser source: • Removal of unwanted hair, for stable long term or permanent hair reduction and for treatment of PFB. The lasers are indicated on all Skin Types Fitzpatrick I-VI including tanned skin. • Photocoagulation and hemostasis of benign pigmented and benign vascular lesions, such as but not limited to port wine stains, hemangioma, warts, teleangiectasia, rosacea, venous lake, leg veins and spider veins. • Coagulation and hemostasis of soft tissue. • Benign pigmented lesions such as, but not limited to, lentigos, (age spots), solar lentigos (sun spots), café au lait macules, seborrheic keratosis, nevi, cloasma, verrucae, skin tags, keratosis and plaques. • The laser is indicated for benign pigmented lesions to reduce lesion size, for patients with lesions that would potentially benefit from aggressive treatment, and for patients with lesions that have not responded to other laser treatments. • The laser is also indicated for the reduction of red pigmentation in hypertrophic and keloid scars where vascularity is an integral part of the scar. • Treatment of wrinkles.”

Which chains run each

Which chains run each: DEKA Motus AZ+ vs DEKA Motus PRO
Attribute	DEKA Motus AZ+	DEKA Motus PRO
Chain adoption	0 recorded pairings	0 recorded pairings
Chains using it	—	—
Approved reviews	0	0

Chain adoption

DEKA Motus AZ+: 0 recorded pairings
DEKA Motus PRO: 0 recorded pairings

Chains using it

DEKA Motus AZ+: —
DEKA Motus PRO: —

Approved reviews

DEKA Motus AZ+: 0
DEKA Motus PRO: 0

Specs and platform

Specs and platform: DEKA Motus AZ+ vs DEKA Motus PRO
Attribute	DEKA Motus AZ+	DEKA Motus PRO
Manufacturer	DEKA	DEKA
Built by (OEM)	DEKA M.E.L.A. S.r.l.	DEKA M.E.L.A. S.r.l.
Category	Dual-wavelength (in-motion)	Alexandrite laser (in-motion)
Technology	755/1064nm Moveo, higher power (Alexandrite)	In-motion alexandrite/Nd:YAG hair removal platform (supersedes Motus AX/AY/AZ+) (Alexandrite)
Launch year	2022	—
Status	Current	Current
Manufacturer source record	No linked source on file.	No linked source on file.

Manufacturer

DEKA Motus AZ+: DEKA
DEKA Motus PRO: DEKA

Built by (OEM)

DEKA Motus AZ+: DEKA M.E.L.A. S.r.l.
DEKA Motus PRO: DEKA M.E.L.A. S.r.l.

Current alternatives

Current catalog models in related categories. Confirm availability and configuration with the supplier.

Lumenis OptiLIGHT

IPL platform

New: —

Cutera Xeo

Multi-app platform

New: $80k–$120k

Cutera Excel HR

Dual-wavelength laser

New: $95k–$135k

InMode Triton

Triple-wavelength diode

New: $100k–$135k

Get a free recommendation Browse by goal

Device and company names are trademarks of their respective owners. The Aesthetic Index is not affiliated with or endorsed by any manufacturer, distributor or lender named here, except as disclosed. Price figures are references, not current offers. Check each device’s source notes. Not medical, legal or regulatory advice.